Pharmacogenetics and Stroke
نویسندگان
چکیده
منابع مشابه
Pharmacogenetics and stroke.
Genetic variations have been shown to influence drug metabolism, risk of adverse drug events, and pharmacodynamic responses for many drugs routinely used to treat patients with stroke or at risk for stroke. Examples include clopidogrel, statins, antihypertensive medications, and coumadin. Further validation studies are needed to assess the clinical utility of selecting drugs and doses based on ...
متن کاملPharmacogenetics and forensic toxicology.
Large inter-individual variability in drug response and toxicity, as well as in drug concentrations after application of the same dosage, can be of genetic, physiological, pathophysiological, or environmental origin. Absorption, distribution and metabolism of a drug and interactions with its target often are determined by genetic differences. Pharmacokinetic and pharmacodynamic variations can a...
متن کاملPharmacogenetics and Pharmacogenomics
The individual differences in response to administered substance (medicament) were observed throughout the whole history of humankind. Pythagoras is thought to be one of the first to observe pharmaco/nutrigenetic interaction as he found out that only some people will get sick after eating fava beans, but others will not. It took approximately 2400 years to elucidate the basis of this observatio...
متن کاملContext, ethics and pharmacogenetics.
Most of the literature on pharmacogenetics assumes that the main problems in implementing the technology will be institutional ones (due to funding or regulation) and that although it involves genetic testing, the ethical issues involved in pharmacogenetics are different from, even less than, 'traditional' genetic testing. Very little attention has been paid to how clinicians will accept this t...
متن کاملPharmacogenetics and Pain Management
More recently, 2 non-cytochrome P450 “pharmacodynamic” genetic tests have been identified that help explain opioid dosage requirements in pain patients. The first measures, opioid mu receptor 1 (OPRM1), which determines the ability of opioids to bind to the mu opioid receptor site. The other measures catechol-o methyltransferase (COMT), the enzyme that degrades catecholamines in the central ner...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Stroke
سال: 2009
ISSN: 0039-2499,1524-4628
DOI: 10.1161/strokeaha.109.562231